Girirajan S, Elsas L J, Devriendt K, Elsea S H
Department of Human Genetics, Virginia Commonwealth University, Richmond, Virginia 23298, USA.
J Med Genet. 2005 Nov;42(11):820-8. doi: 10.1136/jmg.2005.031211. Epub 2005 Mar 23.
Smith-Magenis syndrome (SMS) (OMIM No 182290) is a mental retardation syndrome characterised by behavioural abnormalities, including self injurious behaviours, sleep disturbance, and distinct craniofacial and skeletal anomalies. It is usually associated with deletion involving 17p11.2 and is estimated to occur in 1/25,000 births. Heterozygous frameshift mutations leading to protein truncation in retinoic acid induced 1 gene (RAI1) have been identified in individuals with phenotypic features consistent with SMS. RAI1 lies within the 17p11.2 locus, but these patients did not have 17p11.2 deletions.
Analysis of four individuals with features consistent with SMS for variations in RAI1, using a polymerase chain reaction and sequencing strategy. None of these patients carry 17p11.2 deletions.
Two patients had small deletions in RAI1 resulting in frameshift and premature truncation of the protein. Missense mutations were identified in the other two. Orthologs across other genomes showed that these missense mutations occurred in identically conserved regions of the gene. The mutations were de novo, as all parental samples were normal. Several polymorphisms were also observed, including new and reported SNPs. The patients' clinical features differed from those found in 17p11.2 deletion by general absence of short stature and lack of visceral anomalies. All four patients had developmental delay, reduced motor and cognitive skills, craniofacial and behavioural anomalies, and sleep disturbance. Seizures, not previously thought to be associated with RAI1 mutations, were observed in one patient of the cohort.
Haploinsufficiency of the RAI1 gene is associated with most features of SMS, including craniofacial, behavioural, and neurological signs and symptoms.
史密斯-马吉尼斯综合征(SMS)(在线人类孟德尔遗传数据库编号182290)是一种智力发育迟缓综合征,其特征为行为异常,包括自我伤害行为、睡眠障碍以及独特的颅面和骨骼异常。它通常与17p11.2缺失有关,估计发病率为1/25000活产儿。在具有与SMS一致表型特征的个体中,已鉴定出导致视黄酸诱导1基因(RAI1)中蛋白质截短的杂合移码突变。RAI1位于17p11.2位点,但这些患者没有17p11.2缺失。
采用聚合酶链反应和测序策略,分析四名具有与SMS一致特征的个体的RAI1变异情况。这些患者均无17p11.2缺失。
两名患者的RAI1存在小缺失,导致蛋白质移码和过早截短。另外两名患者鉴定出错义突变。其他基因组的直系同源基因显示,这些错义突变发生在该基因相同的保守区域。这些突变是新生的,因为所有亲本样本均正常。还观察到一些多态性,包括新的和已报道的单核苷酸多态性。患者的临床特征与17p11.2缺失患者不同,总体上没有身材矮小且没有内脏异常。所有四名患者均有发育迟缓、运动和认知技能减退、颅面和行为异常以及睡眠障碍。在该队列的一名患者中观察到癫痫发作,此前认为癫痫发作与RAI1突变无关。
RAI1基因单倍剂量不足与SMS的大多数特征有关,包括颅面、行为和神经体征及症状。